Lack of initiating activity in mutagens which are not carcinogenic. by Coombs, M. M. & Bhatt, T. S.
Br. J. Cancer (1978) 38, 148
Short Communication
LACK OF INITIATING ACTIVITY IN MUTAGENS WHICH
ARE NOT CARCINOGENIC
M. M. COOMBS AND T. S. BHATT
From the Department of Chemistry, Imperial Cancer Research Fund, Lincoln's Inn Fields, London
WC2A 3PX
Received 3 April 1978 Accepted 24 April 1978
WE have recently demonstrated
(Coombs et al., 1976) that there is good
agreement between mutagenicity (as
measured by Ames' test with Salmonella
typhimurium TA 100 with microsomal
activation) and carcinogenicity among 34
closely related polycyclic compounds be-
longing to the cyclopenta[a]phenanthrene
and chrysene series, all synthesized and
tested in these laboratories. Carcinogeni-
city was assayed in all cases by the pro-
duction of skin tumours on application of
a solution of the compound twice weekly
to the shaved dorsal skin of TO mice for
one year, followed by observation for a
second year. Of these 34 compounds, the
19 carcinogens were without exception also
mutagenic; as expected, the majority of
the non-carcinogens were not. However,
there were 6 compounds which were muta-
genic but not carcinogenic (C-M+) in our
test system. On the widely heldtheorythat
tumour initiation is a mutagenic event, it
seemed possible that these compounds
might be incomplete carcinogens, i.e. ini-
tiators which lack promoting activity. In
order to test this idea, 2 or these com-
pounds, (I) and (IV) in Fig. 1, together
with 2 representative carcinogen/muta-
gens (C+M+), (III) and (V), and a non-
carcinogen/non-mutagen (C-M-) (II), have
been retested for tumour production in the
2-stage system, using croton oil as the
promoting agent.
Three-month-old albino TO mice were
assigned to 13 groups by aformal randomi-
sation procedure, each group consisting of
10maleand 10females. Compounds (I)-(V)
were applied in 4 equal doses of 100 lg
each in 40 ,ul of toluene on 4 successive
days, as indicated in the Table (Groups
1-10). Starting one week after the last
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FIG. 1. Compounds tested in the two-stage
system. (I) 15,16-dihydrocyclopenta[a]phe-
nanthren-17-one; (II) 15,16-dihydro-3-
methylcyclopenta[a]phenanthren - 17-one;
(III) 15,16-dihydro-11-methylcyclopenta-
[a]phenanthren-17-one; (IV) 1,2,3,4-tetra-
hydrochrysen-I-one; (V) 1,2,3,4-tetra-
hydro-11-methylchrysen-l-one. (Coombs,
1966; Coombs et al., 1970).NON-CARCINOGENIC MUTAGENS
TABLE.-Number ofmice surviving without tumours, total number ofanimals with tumlours,
and histology ofinduced tumours at site ofapplication. Each group consisted initially of
20 mtice (l0& 10)
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* For Groups 1-10 the dose was 4 x 100 ug, on 4 successive days.
t 1% croton oil in toluene, or toluene alone, was applied twice weekly throughout the experiment.
$ C, carcinoma; P, papilloma.
§ One animal also had a spindle-cell sarcoma.
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FIG. 2. Skin tumours produced with C+M+
compounds. Compound (III): -E-*
promoted with croton oil, Group 4;
-0-0- "promoted" with toluene, Group
3; -+-+- repeated doses of (III), Group
13. Compound (V): -A-A-promotedwith
croton oil, Group 10; A- A- "promoted"
with toluene, Group 9.
application, Groups 2, 4, 6, 8 and 10 were
promoted twice weekly until the end ofthe
experiment with 10 ,ul ofa 1% v/v solution
ofcroton oilintoluene, applied to the same
dorsal region as the initiating doses.
Groups 1, 3, 5, 7 and 9 were similarly
treated with toluene alone. The control
groups 11 and 12 received toluene, or
croton oil and toluene, as above. Mice in
Group 13 were treated with the carcinogen
(III) by the method used previously,
namely twice weekly with 50 ,ug of (III)
in 10 ul of toluene, without the use of
croton oil. General conditions were those
used then, and tumours were classified
histologically as described (Coombs et al.,
1973).
The Table shows the number of animals
surviving without tumours in all the
groups, and the number and type of tu-
mours observed. Croton oil itself (Group
12) was not carcinogenic and had no effect
on survival. Only the known carcinogens
(III) and (V) produced skin tumours; none
was observed with either the non-carcino-
gen/mutagens (I) and (IV) or the non-
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carcinogen/non-mutagen (II), and again
survival of these animals was similar to
that ofthe control groups (11 and 12). The
time offirst appearance oftheskintumours
induced by compounds (III) and (V) is
depicted in Fig. 2. At this initiating dose
(400 ,g) only a few tumours were observed
when the mice were treated subsequently
with toluene alone, and these tumours
appeared late. When promotion with
croton oil was used, the tumour incidence
was 90% with both (III) and (V), and the
latent periods of the tumours were similar
to those of the skin tumours produced by
repeated treatment with (III) (Group 13)
under the conditions previously used.
However, all the tumours examined histo-
logically from Group 13 were carcinomas,
as judged by the criterion oftumour inva-
sion of the panniculus carnosus muscle,
whereas tumours from the croton-oil-
treated animals (Groups 4 and 10) con-
sisted 60% carcinomas and 40% papil-
lomas.
Thus, it appears that the mutagens (I)
and (IV) are not initiating agents, at least
under conditions where the carcinogens
(III) and (V) are very active. Although we
have noinformation on therelativeextents
to which these compounds are metabolized
by mouse shin cells to reactive metabolites
that bind to DNA in vivo, the same initiat-
ing dose was used because compounds (I)
and (III)-(V) give comparable numbers of
revertants in Ames' test (Coombs et al.,
1976). Moreover, it is known that com-
pounds (I) and (III) are metabolized to a
similar extent by rat liver microsomes in
vitro, and bind to a similar extent to DNA
added to these incubations (Coombs et al.,
1975). There is no reason to suppose that
(I) and (IV) are not representative of the
4 other mutagens/non-carcinogens (C-M+)
in the original collection. These 34 closely
related compounds may be classified into
3 sets: C+M+, C-M+ and C-M-. No mem-
ber of the fourth possible combination
(C+M-) has been observed by us, although
such compounds have been reported and
discussed by others (McCann and Ames,
1976; Purchase et al., 1976).
C-M+ compounds such as (I) are capable
of metabolic activation to active species
that bind covalently to DNA in vitro and
cause mutation in bacteria. Presumably
in the animal cell other factors operate to
prevent these active metabolites from
damaging the genetic material.
We are indebted to Dr L. Pang for confirming the
pathology of the induced skin tumours, and we wish
to thank Miss J. Macdonald for valuable assistance.
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